Etripamil Gets FDA Approval for At-Home Tachycardia Conversion

Etripamil Gets FDA Approval for At-Home Tachycardia Conversion

(MedPage Today) -- The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), maker Milestone Pharmaceuticals announced. The rapid-acting L-type calcium channel blocker is indicated...

Etripamil Becomes First, Only Self-Administered Nasal Spray Approved for PSVT

FDA has approved etripamil as the first and only self-administered nasal spray for adults with paroxysmal supraventricular tachycardia (PSVT), offering a rapid, effective treatment that can be used outside of health care settings.

FDA Approves Etripamil as First At-Home Option for Paroxysmal Supraventricular Tachycardia

FDA approves etripamil nasal spray, offering a rapid, self-administered solution for adults with paroxysmal supraventricular tachycardia (PSVT).